Pages that link to "Q27011574"
Jump to navigation
Jump to search
The following pages link to Antibodies in HIV-1 vaccine development and therapy (Q27011574):
Displaying 50 items.
- Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10 (Q21089590) (← links)
- HIV-Host Interactions: Implications for Vaccine Design (Q26765966) (← links)
- Recent update in HIV vaccine development (Q26766628) (← links)
- Contrasting Adult and Infant Immune Responses to HIV Infection and Vaccination (Q26776518) (← links)
- Human immunodeficiency virus/acquired immune deficiency syndrome: Using drug from mathematical perceptive (Q26777042) (← links)
- The role of Fc-FcγR interactions in IgG-mediated microbial neutralization (Q26797466) (← links)
- Structural insights on the role of antibodies in HIV-1 vaccine and therapy (Q26829461) (← links)
- Serology in the 21st century: the molecular-level analysis of the serum antibody repertoire (Q26997997) (← links)
- Primary immunoglobulin repertoire development: time and space matter (Q27022157) (← links)
- Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection (Q27022652) (← links)
- Virological features associated with the development of broadly neutralizing antibodies to HIV-1 (Q27025177) (← links)
- HIV broadly neutralizing antibody targets (Q27026662) (← links)
- AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity (Q27318266) (← links)
- HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization (Q27324184) (← links)
- Elimination of HIV-1-infected cells by broadly neutralizing antibodies (Q27329126) (← links)
- Structural Basis for Enhanced HIV-1 Neutralization by a Dimeric Immunoglobulin G Form of the Glycan-Recognizing Antibody 2G12 (Q27680810) (← links)
- Structure and Immunogenicity of a Peptide Vaccine, Including the Complete HIV-1 gp41 2F5 Epitope (Q27681352) (← links)
- Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike (Q27683540) (← links)
- Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers (Q27683553) (← links)
- Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor (Q27684529) (← links)
- Somatic Hypermutation-Induced Changes in the Structure and Dynamics of HIV-1 Broadly Neutralizing Antibodies (Q27723297) (← links)
- Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies (Q28066335) (← links)
- New concepts in HIV-1 vaccine development (Q28067027) (← links)
- Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design (Q28075274) (← links)
- Antibodies for HIV prevention in young women (Q28082033) (← links)
- Cross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes B, F1, C or the B/Bbr Variant in Relation to the Genetics and Biochemical Characteristics of the env Gene (Q28554907) (← links)
- Counteraction of the multifunctional restriction factor tetherin (Q28659945) (← links)
- HIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmission (Q28660329) (← links)
- Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies. (Q30352300) (← links)
- Computational tools for epitope vaccine design and evaluation (Q30373339) (← links)
- Darwin and Fisher meet at biotech: on the potential of computational molecular evolution in industry (Q30388839) (← links)
- Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System (Q33592852) (← links)
- Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys (Q33597744) (← links)
- Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy (Q33611645) (← links)
- Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters. (Q33638320) (← links)
- Which Antibody Functions are Important for an HIV Vaccine? (Q33772637) (← links)
- Antibody 10-1074 suppresses viremia in HIV-1-infected individuals (Q33786443) (← links)
- Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller (Q33786447) (← links)
- A cryptic polyreactive antibody recognizes distinct clades of HIV-1 glycoprotein 120 by an identical binding mechanism (Q33793007) (← links)
- Abnormal B cell memory subsets dominate HIV-specific responses in infected individuals (Q33808304) (← links)
- A human inferred germline antibody binds to an immunodominant epitope and neutralizes Zika virus (Q33825684) (← links)
- Transplanting supersites of HIV-1 vulnerability (Q33854841) (← links)
- Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization (Q33946158) (← links)
- Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120. (Q34146374) (← links)
- Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity (Q34204325) (← links)
- Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques (Q34230556) (← links)
- Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes (Q34262089) (← links)
- Thermodynamic analysis of the binding of 2F5 (Fab and immunoglobulin G forms) to its gp41 epitope reveals a strong influence of the immunoglobulin Fc region on affinity (Q34389587) (← links)
- Probing the effect of force on HIV-1 receptor CD4. (Q34419964) (← links)
- Insights into vaccine development for acquired immune deficiency syndrome from crystal structures of human immunodeficiency virus-1 gp41 and equine infectious anemia virus gp45. (Q34485027) (← links)